SER
Serina Therapeutics, Inc.Healthcare·Biotechnology
--
$0M market cap
Revenue
$0.0M
Free Cash Flow
$-10.6M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. wa
2-Year Price History
$1.98-80.2%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -6.3 | -6.3 | -6.9 | -4.6 | -4.6 | -0.0 | 24.5 | 3.2 | 12.1 | -120.6% | -33.1x | -- |
| Act | 2025-Q4 | 0.0 | -3.1 | -6.2 | -3.3 | -6.0 | -6.0 | -0.0 | 4.8 | 3.1 | 10.2 | -790.2% | -15.6x | -- |
Valuation & Metrics
Market Stats
Price--
Market Cap$0M
Enterprise Value$-21M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield0.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-10.2M
Free Cash Flow$-10.6M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-455.4%
WC Change % Rev0.0%
Interest Coverage-1039.8x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.3M
Days to Cover4.1
Change (vs Prior)-21.4%
Need at least 2 settlement dates for chart
Employees
Headcount12
Revenue / Employee$0
Gross Profit / Employee$-1,500
Cash Runway
27.7months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
11.0%(+4.5% YoY)
16 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
3.2%(-0.2% YoY)
6 filers
Vanguard, iShares, SPDR
Market makers
0.4%(+0.4% YoY)
2 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Sio Capital Management, LLC | $1.9M | $1.94 | +$1.9M | +$1.9M | -1.2% | $694M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $309K | $1.94 | +$309K | +$309K | — | $4.04T |
| Waverly Advisors, LLC | $131K | $7.70 | +$0 | +$0 | -0.2% | $13.31B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $126K | $5.01 | +$67K | +$69K | +2.3% | $1.61T |
| BlackRock, Inc.Passive | $113K | $2.93 | +$80K | +$107K | -0.2% | $5.69T |
| JANE STREET GROUP, LLCMM | $77K | $1.94 | +$77K | +$77K | -0.1% | $92.10B |
| VANGUARD FIDUCIARY TRUST COPassive | $39K | $1.94 | +$39K | +$39K | — | $395.83B |
| Avidian Wealth Solutions, LLC | $36K | $1.94 | +$36K | +$36K | +0.2% | $3.15B |
| STATE STREET CORPPassive | $25K | $5.36 | +$0 | +$25K | -0.2% | $2.89T |
| Caitong International Asset Management Co., Ltd | $8K | $1.94 | +$8K | +$8K | +1.3% | $540M |
| WELLS FARGO & COMPANY/MN | $7K | $2.09 | +$0 | +$7K | -0.2% | $497.71B |
| ADVISOR GROUP HOLDINGS, INC. | $2K | $2.07 | +$2K | +$2K | -0.3% | $67.63B |
| Tower Research Capital LLC (TRC)MM | $2K | $8.03 | +$0 | −$0 | -0.6% | $3.84B |
| Vanguard Global Advisers, LLCPassive | $0 | $1.94 | +$0 | +$0 | — | $186.48B |
| Piscataqua Savings Bank | $0 | $9.58 | +$0 | +$0 | -0.4% | $142M |
| Advisory Services Network, LLC | $0 | $5.36 | +$0 | +$0 | -0.9% | $7.52B |
| MORGAN STANLEY | $0 | $11.53 | +$0 | +$0 | -0.3% | $1.65T |
| ALBION FINANCIAL GROUP /UT | $0 | $13.46 | +$0 | +$0 | -0.1% | $1.52B |
| Pacifica Partners Inc. | $0 | $9.58 | +$0 | +$0 | +0.5% | $301M |
| UBS Group AG | $0 | $5.72 | −$0 | −$1K | -0.3% | $562.11B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-1.10%
avg per quarter
Holders (ex-self)
-1.10%
excl. this stock
Buyers (this Q)
-1.16%
14 buyers · $0.00B in
Sellers (this Q)
-0.28%
1 sellers · $0.00B out
alpha coverage: 88% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+2.6%
how holders react when this stock falls
On quiet Qs
-16.6%
−10% to +10% baseline
On rallies (+10%+)
-0.2%
how they react when this stock rises
Holders' portfolio flow this Q
+11.5%
inflows — adds are organic
Sellers' portfolio flow this Q
+14.3%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
+6.6%
Holder mid (any stock)
-2.0%
Holder rally (any stock)
-16.6%
Biggest decreases this quarter
New buyers this quarter
Sio Capital Management, LLC+$0.00Bα-1.2VANGUARD CAPITAL MANAGEMENT LLC+$0.00BJANE STREET GROUP, LLC+$0.00Bα-0.1VANGUARD FIDUCIARY TRUST CO+$0.00BAvidian Wealth Solutions, LLC+$0.00Bα+0.2Caitong International Asset Management Co., Ltd+$0.00Bα+1.3Vanguard Global Advisers, LLC+$0.00BFarther Finance Advisors, LLC+$0.00Bα-0.9Federation des caisses Desjardins du Quebec+$0.00Bα-0.3
Top-5 holders · 93.0%
Sio Capital Management, LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
Waverly Advisors, LLC--
GEODE CAPITAL MANAGEMENT, LLC--
BlackRock, Inc.--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Sio Capital Management, LLC1.0MBROADWOOD CAPITAL INC—Waverly Advisors, LLC67KHighTower Advisors, LLC—MILLENNIUM MANAGEMENT LLC—Keel Point, LLC—Linscomb & Williams, Inc.—CITADEL ADVISORS LLC—Avidian Wealth Solutions, LLC19KTORONTO DOMINION BANK—
Analyst Coverage
Analyst Coverage
Analyst Ratings
1
Buy: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$20K
1 txn · 1 insider · 12,183 sh
Sells ($, 12mo)
$1.12M
41 txns · 1 insider · 253,500 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-19 | BUY | Marshall Richard Peter | director | 12,183 | $1.65 | $20K | $20K |
| 2026-03-23 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 6,500 | $2.86 | $19K | $0 |
| 2026-03-19 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 39,000 | $2.50 | $98K | $0 |
| 2026-02-02 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 6,500 | $3.03 | $20K | $0 |
| 2026-01-28 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 6,500 | $3.57 | $23K | $0 |
| 2026-01-22 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 2,500 | $2.95 | $7K | $0 |
| 2026-01-21 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 2,000 | $3.00 | $6K | $0 |
| 2026-01-20 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 2,000 | $3.07 | $6K | $0 |
| 2026-01-14 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 1,084 | $2.50 | $3K | $0 |
| 2026-01-13 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 5,416 | $2.50 | $14K | $0 |
| 2026-01-08 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 13,000 | $2.69 | $35K | $0 |
| 2025-12-23 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 4,100 | $2.60 | $11K | $0 |
| 2025-12-22 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 5,673 | $2.67 | $15K | $0 |
| 2025-12-16 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 3,227 | $2.96 | $10K | $0 |
| 2025-12-12 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 1,700 | $3.26 | $6K | $0 |
| 2025-12-11 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 3,555 | $3.24 | $12K | $0 |
| 2025-12-10 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 645 | $3.35 | $2K | $0 |
| 2025-12-09 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 600 | $3.31 | $2K | $0 |
| 2025-12-03 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 5,000 | $3.52 | $18K | $0 |
| 2025-12-02 | SELL | Moreadith Randall | officer: Chief Scientific Officer | 1,500 | $3.91 | $6K | $0 |
Order Flow (FINRA, ~3w lag)
58.9%retail-3.8pp
4.1%dark+2.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Serina Therapeutics: A Captive Finance Playpen Facing a Regulatory Wall
Overall Risk
9/10
Fraud
4/10
Dilution
10/10
Insolvency
9/10
Earnings Overstated
3/10
Hidden Liabilities
8/10
Legal
6/10
Audit Warnings
9/10
Hidden Upside
2/10
Contextually Acceptable
3/10